Q4 Earnings Forecast for OPCH Issued By Barrington Research

Option Care Health, Inc. (NASDAQ:OPCH - Free Report) - Equities researchers at Barrington Research dropped their Q4 2024 EPS estimates for shares of Option Care Health in a note issued to investors on Thursday, October 31st. Barrington Research analyst M. Petusky now forecasts that the company will earn $0.32 per share for the quarter, down from their prior forecast of $0.34. Barrington Research currently has a "Outperform" rating and a $32.00 target price on the stock. The consensus estimate for Option Care Health's current full-year earnings is $1.22 per share. Barrington Research also issued estimates for Option Care Health's Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.28 EPS, Q3 2025 earnings at $0.30 EPS and Q4 2025 earnings at $0.34 EPS.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.05. Option Care Health had a return on equity of 15.30% and a net margin of 4.37%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.22 billion.

A number of other equities analysts have also weighed in on OPCH. Jefferies Financial Group lowered shares of Option Care Health from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $38.00 to $26.00 in a report on Thursday. Truist Financial decreased their price target on Option Care Health from $41.00 to $34.00 and set a "buy" rating for the company in a research note on Friday. JMP Securities increased their price objective on Option Care Health from $36.00 to $37.00 and gave the company a "market outperform" rating in a research report on Monday, September 30th. Finally, Bank of America lowered Option Care Health from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $43.00 to $29.00 in a research report on Wednesday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $31.60.

Option Care Health Stock Up 4.6 %

Option Care Health stock traded up $1.07 during trading hours on Friday, hitting $24.11. The stock had a trading volume of 7,118,017 shares, compared to its average volume of 1,473,412. The stock's 50-day moving average price is $30.65 and its 200-day moving average price is $29.97. Option Care Health has a 12-month low of $22.84 and a 12-month high of $34.63. The company has a quick ratio of 1.36, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $4.12 billion, a P/E ratio of 19.36, a price-to-earnings-growth ratio of 1.79 and a beta of 1.29.

Insiders Place Their Bets

In related news, CFO Michael H. Shapiro sold 23,217 shares of the firm's stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.95, for a total value of $718,566.15. Following the transaction, the chief financial officer now owns 247,317 shares of the company's stock, valued at approximately $7,654,461.15. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Michael H. Shapiro sold 23,217 shares of the company's stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $30.95, for a total value of $718,566.15. Following the completion of the sale, the chief financial officer now directly owns 247,317 shares in the company, valued at $7,654,461.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Elizabeth Quadros Betten sold 47,531 shares of Option Care Health stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $31.09, for a total value of $1,477,738.79. Following the transaction, the director now owns 21,339 shares in the company, valued at $663,429.51. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.64% of the company's stock.

Institutional Investors Weigh In On Option Care Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. UMB Bank n.a. increased its stake in shares of Option Care Health by 937.5% in the third quarter. UMB Bank n.a. now owns 830 shares of the company's stock worth $26,000 after purchasing an additional 750 shares in the last quarter. GAMMA Investing LLC increased its stake in Option Care Health by 110.6% in the 3rd quarter. GAMMA Investing LLC now owns 897 shares of the company's stock worth $28,000 after buying an additional 471 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in Option Care Health by 3,362.8% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 1,489 shares of the company's stock valued at $47,000 after acquiring an additional 1,446 shares during the period. Blue Trust Inc. lifted its position in shares of Option Care Health by 14.8% in the second quarter. Blue Trust Inc. now owns 2,931 shares of the company's stock valued at $81,000 after acquiring an additional 377 shares in the last quarter. Finally, SageView Advisory Group LLC bought a new position in shares of Option Care Health in the first quarter worth about $85,000. Institutional investors own 98.05% of the company's stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.